Palvella Therapeutics, Inc.
QTORIN™ rapamycin
microcystic lymphatic malformations
Countdown
358days
Approval decision · ~ Jun 30, 2027 estimated
What's at stake
A final FDA approval decision on QTORIN™ rapamycin for microcystic lymphatic malformations is expected ~ Jun 30, 2027.
Primary source
· SEC 8-K
verified 14h ago
“Potential FDA approval 1H 2027”